Skip to main content
Top
Literature
1.
go back to reference Miyazaki M, Tamura M, Kabashima N, Serino R, Shibata T, Miyamoto T, et al. Minimal change nephrotic syndrome in a patient with strongyloidiasis. Clin Exp Nephrol. 2010;14:367–71.CrossRef Miyazaki M, Tamura M, Kabashima N, Serino R, Shibata T, Miyamoto T, et al. Minimal change nephrotic syndrome in a patient with strongyloidiasis. Clin Exp Nephrol. 2010;14:367–71.CrossRef
2.
go back to reference Rotolo U, Scarlata F, Giordano S, Tortorici C, Bono L, Coglitore M, et al. Nephrotic syndrome and Gram-negative sepsis in a patient with strongyloidiasis: a case report. Infez Med. 2007;1:59–62. Rotolo U, Scarlata F, Giordano S, Tortorici C, Bono L, Coglitore M, et al. Nephrotic syndrome and Gram-negative sepsis in a patient with strongyloidiasis: a case report. Infez Med. 2007;1:59–62.
Metadata
Title
Comment about nephrotic syndrome in association with strongyloidiasis
Authors
Gioacchino Li Cavoli
Calogera Tortorici
Luisa Bono
Angelo Ferrantelli
Carlo Giammarresi
Ugo Rotolo
Publication date
01-06-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0442-0

Other articles of this Issue 3/2011

Clinical and Experimental Nephrology 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine